Acumen Pharmaceuticals, Inc. - Common Stock (ABOS)

Sabirnetug topline results expected November 2026 for early Alzheimer's disease trial.

Acumen Pharmaceuticals (NASDAQ:ABOS) said it expects to report top-line results in November from its Phase II ALTITUDE-AD trial of sabirnetug, an investigational antibody designed to target soluble amyloid-beta oligomers in patients with Alzheimer’s disease. Chief Executive Officer Dan O’Connell sa

Acumen Pharmaceuticals (NASDAQ:ABOS) said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer’s disease. Chief Executive Offic

Acumen (ABOS) Q1 2026 Earnings Transcript

Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer’s disease pipeline. On the company’s first-quarter 2026 earnings call, Chief Executive Offic

Acumen Pharmaceuticals posts better-than-expected Q3 2025 results, advancing its Alzheimer's treatment pipeline with cash into 2027.

Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.

ABOS stock results show that Acumen Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.